ASOs are specifically designed to target PLN mRNA, downregulating PLN activity and its interaction with SERCA2a in heart failure murine models, preventing left ventricular dilatation, improving left ventricular contractility, and leading to an increase in survival rate [66]. This evidence concerns the gene PLN and Left ventricular dilatation.